Maurizio Averna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8884668/publications.pdf

Version: 2024-02-01

277	15,703	34016 52	19136 118
papers	citations	h-index	g-index

286	286	286	13368
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. European Journal of Preventive Cardiology, 2022, 28, 1864-1872.	0.8	19
2	Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 17-20.	1.1	4
3	One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?. European Journal of Internal Medicine, 2022, 95, 1-4.	1.0	4
4	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. European Journal of Preventive Cardiology, 2022, 29, 721-729.	0.8	5
5	LIfeSTyle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	3
6	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
7	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. Atherosclerosis, 2022, 347, 63-67.	0.4	5
8	Twelve Variants Polygenic Score for Lowâ€Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	1.6	12
9	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Archives of Medical Science, 2022, 18, 285-292.	0.4	13
10	Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease. Reviews in Cardiovascular Medicine, 2022, 23, 156.	0.5	0
11	Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects. Journal of Clinical Lipidology, 2022, 16, 530-537.	0.6	3
12	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	3
13	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	2.7	21
14	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. Endocrine, 2021, 71, 344-350.	1.1	9
15	Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 137-144.	1.1	10
16	Welcome Editorial. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1.	1.1	0
17	DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network analysis. PLoS ONE, 2021, 16, e0247402.	1.1	1
18	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life, 2021, 11, 315.	1.1	8

#	Article	IF	Citations
19	Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. Internal Medicine Journal, 2021, 51, 585-590.	0.5	1
20	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
21	rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1542-1547.	1.1	7
22	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. Life, 2021, 11, 581.	1.1	11
23	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. Atherosclerosis, 2021, 331, e181.	0.4	0
24	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
25	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. Atherosclerosis Plus, 2021, 43, 7-9.	0.3	5
26	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	1.2	12
27	Resistive index of ophthalmic artery as anÂimaging biomarker of hypertension-related vascular and kidney damage. Biomarkers in Medicine, 2021, 15, 1155-1166.	0.6	2
28	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Failure Clinics, 2021, 18, 177-188.	1.0	14
29	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	5.5	114
30	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study. Atherosclerosis, 2020, 292, 209-214.	0.4	6
31	NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-Î± and LXR agonists. Molecular and Cellular Biochemistry, 2020, 473, 247-262.	1.4	13
32	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.4	25
33	Mutation in candidate genes account for a small minority of hypobetalipoproteinemias and NGS analysis support polygenicity in mutation-negative patients. Atherosclerosis, 2020, 315, e45.	0.4	0
34	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides. An in vitro study. Atherosclerosis, 2020, 315, e258.	0.4	0
35	Automated untargeted stable isotope assisted lipidomics of liver cells on high glucose shows alteration of sphingolipid kinetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158656.	1.2	1
36	Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regulated at the transcriptional level. Journal of Diabetes and Metabolic Disorders, 2020, 19, 363-371.	0.8	3

#	Article	IF	Citations
37	Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis, 2020, 308, 32-38.	0.4	8
38	Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Current Medicinal Chemistry, 2020, 27, 3773-3783.	1.2	3
39	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. Atherosclerosis Supplements, 2020, 42, e35-e40.	1.2	10
40	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. Journal of Clinical Lipidology, 2019, 13, 735-743.	0.6	1
41	Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1068-1076.	1.1	10
42	Resting Energy Expenditure and Substrate Oxidation in Malnourished Patients With Type 1 Glycogenosis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5566-5572.	1.8	1
43	Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 822-829.	1.1	28
44	Is echocardiography mandatory for patients with chronic kidney disease?. Internal and Emergency Medicine, 2019, 14, 923-929.	1.0	8
45	Liver and Statins: A Critical Appraisal of the Evidence. Current Medicinal Chemistry, 2019, 25, 5835-5846.	1.2	16
46	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.4	31
47	An irregular atrial tachycardia. Netherlands Heart Journal, 2018, 26, 102-103.	0.3	0
48	Lipoprotein-associated phospholipase Aâ,, activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 517-523.	1.1	6
49	Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288.	1.2	38
50	An irregular atrial tachycardia. Netherlands Heart Journal, 2018, 26, 106-108.	0.3	0
51	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	1.0	29
52	Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred. Journal of Clinical Lipidology, 2018, 12, 145-151.	0.6	8
53	Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis. Frontiers in Physiology, 2018, 9, 1222.	1.3	10
54	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48

#	Article	IF	Citations
55	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	0.5	4
56	Clinical and genetic features of familial hypercholesterolemia in pediatric patients: The lipigen Study. Atherosclerosis, 2018, 275, e98-e99.	0.4	0
57	Diabetes and aortic root dimension: A controversial subject. International Journal of Cardiology, 2018, 264, 190.	0.8	0
58	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. Cardiovascular Research, 2018, 114, 1595-1604.	1.8	9
59	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.4	131
60	Diagnostic algorithm for familial chylomicronemia syndrome. Atherosclerosis Supplements, 2017, 23, 1-7.	1.2	94
61	Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. Journal of Clinical Lipidology, 2017, 11, 272-281.e8.	0.6	18
62	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal, 2017, 189, 120-127.	1.2	10
63	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	1.3	56
64	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis Supplements, 2017, 26, 16-24.	1.2	24
65	Differences in Cardiac Structure and Function Between Black and White Patients: Another Step in the Evaluation of Cardiovascular Risk in Chronic Kidney Disease. American Journal of Hypertension, 2017, 30, 770-771.	1.0	2
66	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.4	19
67	Response to treatment and occurrence of cardiovascular (cv) complications in patients with autosomal recessive hypercholesterolemia (arh): A retrospective analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e18-e19.	1.1	0
68	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
69	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
70	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat Î²-Cells. Direct Effect of Oxidative Stress. Scientific Reports, 2017, 7, 11863.	1.6	59
71	The odyssey apprise trial: rationale, design and interim data. Atherosclerosis, 2017, 263, e25.	0.4	0
72	FIrst interim results of the global, longitudinal, pharmaco-epidemiologic, observational registry on gene therapy in the management of lipoprotein lipase deficiency (geniall). Atherosclerosis, 2017, 263, e66-e67.	0.4	1

#	Article	IF	Citations
73	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
74	Characterization of Italian patients with familial hypercholesterolemia: The lipigen study. Atherosclerosis, 2017, 263, e235.	0.4	0
75	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3340-3348.	1.8	29
76	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: AÂcomparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. Journal of Clinical Lipidology, 2017, 11, 1234-1242.	0.6	34
77	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterolâ€“diabetes connection? A systematic review of literature. Acta Diabetologica, 2017, 54, 111-122.	1.2	19
78	Inverse association between type 2 diabetes and aortic root dimension in hypertensive patients. International Journal of Cardiology, 2017, 228, 233-237.	0.8	8
79	Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 161-167.	1.1	45
80	The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. Atherosclerosis, 2017, 262, 146-153.	0.4	18
81	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€“therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
82	ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND WITH OR WITHOUT CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF 10 ODYSSEY RANDOMIZED TRIALS. Canadian Journal of Cardiology, 2017, 33, S115-S116.	0.8	0
83	Albumin versus solvent/detergentâ€“treated pooled plasma as replacement fluid for longâ€term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitis. Transfusion, 2016, 56, 755-760.	0.8	6
84	FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheimer's disease. Analytical and Bioanalytical Chemistry, 2016, 408, 2215-2226.	1.9	4
85	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis, 2016, 244, 138-146.	0.4	163
86	Lomitapide affects HDL composition and function. Atherosclerosis, 2016, 251, 15-18.	0.4	9
87	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	1.1	23
88	Baseline metabolic disturbances and the twenty-five years risk of incident cancer in a Mediterranean population. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1020-1025.	1.1	14
89	Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up. Indian Journal of Gastroenterology, 2016, 35, 236-241.	0.7	11
90	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 36-44.	1.1	16

#	Article	IF	Citations
91	Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 371-379.	1.2	5
92	Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model. Atherosclerosis, 2016, 246, 50-56.	0.4	16
93	Issues Affecting Quality of Life and Disease Burden in Lipoprotein Lipase Deficiency (Lpld) â€“ First Step Towards a Pro Measure in Lpld. Value in Health, 2015, 18, A707.	0.1	4
94	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic endâ€stage renal disease patients. Hemodialysis International, 2015, 19, 360-367.	0.4	5
95	Role of Nutraceuticals in Hypolipidemic Therapy. Frontiers in Cardiovascular Medicine, 2015, 2, 22.	1.1	22
96	The pathophysiology of intestinal lipoprotein production. Frontiers in Physiology, 2015, 6, 61.	1.3	33
97	Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. Atherosclerosis, 2015, 241, 79-86.	0.4	55
98	The effect of ezetimibe on NAFLD. Atherosclerosis Supplements, 2015, 17, 27-34.	1.2	19
99	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Atherosclerosis, 2015, 239, 209-217.	0.4	17
100	Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scandinavian Journal of Gastroenterology, 2015, 50, 347-354.	0.6	20
101	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
102	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499.	13.9	1,838
103	Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Journal of Clinical Lipidology, 2015, 9, 607-617.	0.6	40
104	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia â€“ A post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis, 2015, 240, 408-414.	0.4	36
105	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
106	Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2694-2699.	1.1	20
107	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	1.4	15
108	Lipid Peroxidation, Nitric Oxide Metabolites, and Their Ratio in a Group of Subjects with Metabolic Syndrome. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-8.	1.9	15

#	Article	IF	Citations
109	Lomitapide: a novel drug for homozygous familial hypercholesterolemia. Clinical Lipidology, 2014, 9, 19-32.	0.4	11
110	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
111	Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk. Current Atherosclerosis Reports, 2014, 16, 414.	2.0	20
112	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atherosclerosis Supplements, 2014, 15, 33-45.	1.2	27
113	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473
114	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
115	Behavior of the total antioxidant status in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 166-169.	1.8	5
116	eNOS Activation by HDL Is Impaired in Genetic CETP Deficiency. PLoS ONE, 2014, 9, e95925.	1.1	31
117	Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis, 2013, 227, 342-348.	0.4	128
118	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetologica, 2013, 50, 241-249.	1.2	48
119	Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia. American Journal of Cardiology, 2013, 112, 1885-1895.	0.7	45
120	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	6.3	624
121	Oxidative status in nondiabetic middle-aged subjects with metabolic syndrome: Preliminary data. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e17-e18.	1.1	2
122	Protein oxidation in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2013, 7, 38-41.	1.8	12
123	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
124	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Journal of Lipid Research, 2013, 54, 3481-3490.	2.0	76
125	The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. Diabetes Care, 2013, 36, 2850-2856.	4.3	51
126	A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2021-2025.	1.1	73

#	Article	IF	Citations
127	Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Lowâ€HDL Phenotype. Journal of the American Heart Association, 2013, 2, e000063.	1.6	28
128	Familial combined hypolipidemia due to mutations in theANGPTL3gene. Clinical Lipidology, 2013, 8, 81-95.	0.4	5
129	Gelatinases and Their Tissue Inhibitors in a Group of Subjects With Metabolic Syndrome. Journal of Investigative Medicine, 2013, 61, 978-983.	0.7	43
130	Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 805-809.	1.1	80
131	Lipid and Apoprotein Composition of HDL in Partial or Complete CETP Deficiency. Current Vascular Pharmacology, 2012, 10, 422-431.	0.8	8
132	Lipidâ€Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in Highâ€Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovascular Therapeutics, 2012, 30, 61-74.	1.1	15
133	The ANP Genetic Variant RS5068 is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. Journal of Cardiac Failure, 2012, 18, S65-S66.	0.7	0
134	Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. Journal of Translational Medicine, 2012, 10, 235.	1.8	35
135	Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 132-135.	1.8	21
136	Clinical utility of novel biomarkers for cardiovascular disease risk stratification. Internal and Emergency Medicine, 2012, 7, 263-270.	1.0	5
137	Statin therapy in patients with aortic stenosis after the ASTRONOMER trial: is there still any space?. Internal and Emergency Medicine, 2012, 7, 35-36.	1.0	2
138	Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. Acta Diabetologica, 2012, 49, 145-151.	1.2	10
139	Prevalence of â€˜Borderlineâ€™ Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 43-51.	1.0	3
140	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. Journal of the American College of Cardiology, 2011, 58, 629-636.	1.2	91
141	Plasma non-cholesterol sterols in primary hypobetalipoproteinemia. Atherosclerosis, 2011, 216, 409-413.	0.4	8
142	Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia. Annals of Hepatology, 2011, 10, 221-226.	0.6	16
143	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. Combination Products in Therapy, 2011, 1, 1.	1.1	3
144	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical Biochemistry, 2011, 44, 627-634.	0.8	3

#	Article	IF	Citations
145	Hypobetalipoproteinemia. Advances in Clinical Chemistry, 2011, 54, 81-107.	1.8	101
146	Lipase maturation factor 1 is required for endothelial lipase activity. Journal of Lipid Research, 2011, 52, 1162-1169.	2.0	21
147	Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 2011, 8, 262-270.	0.9	12
148	Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Advances in Clinical Chemistry, 2011, 54, 81-107.	1.8	32
149	Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. Metabolism: Clinical and Experimental, 2010, 59, 463-467.	1.5	21
150	Postprandial hyperglycemia is a determinant of platelet activation in early typeÂ2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2010, 8, 828-837.	1.9	74
151	Plasma Nonâ€“cholesterol Sterols: A Useful Diagnostic Tool in Pediatric Hypercholesterolemia. Pediatric Research, 2010, 67, 200-204.	1.1	15
152	Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C. Journal of Clinical Lipidology, 2010, 4, 204-205.	0.6	0
153	Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency. Journal of Clinical Lipidology, 2010, 4, 207-208.	0.6	0
154	Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. Journal of Clinical Lipidology, 2010, 4, 272-278.	0.6	10
155	The production of 85kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apob gene occurs by ALLN-inhibitable protease cleavage during translocation. Biochemical and Biophysical Research Communications, 2010, 398, 665-670.	1.0	6
156	A novel component of the metabolic syndrome: The oxidative stress. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 72-77.	1.1	292
157	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis, 2010, 208, 177-182.	0.4	74
158	Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids in Health and Disease, 2010, 9, 127.	1.2	6
159	A novel putative interactor for the low density lipoprotein receptor cytoplasmic domain. Molecular Medicine Reports, 2010, 3, 341-5.	1.1	0
160	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4584-4590.	1.8	52
161	Lipid-altering efficacy of ezetimibe/simvastatin 10/20â€ƒmg compared with rosuvastatin 10â€ƒmg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice, 2009, 63, 547-559.	0.8	62
162	C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clinical Biochemistry, 2009, 42, 1713-1718.	0.8	30

#	Article	IF	Citations
163	Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 321-326.	1.1	10
164	Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: A multicenter Italian study. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 84-90.	1.1	68
165	Down regulation of CD11b and CD18 expression in children with hypercholesterolemia: A preliminary report. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 105-109.	1.1	4
166	Obesity and the metabolic syndrome in a student cohort from Southern Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 620-625.	1.1	20
167	Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia. Atherosclerosis, 2009, 204, 202-207.	0.4	26
168	Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. Atherosclerosis, 2009, 206, 193-198.	0.4	22
169	The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: Results of a 15 years follow-up in a Mediterranean population. Atherosclerosis, 2008, 197, 147-153.	0.4	42
170	Genetics of familial hypobetalipoproteinemia. Future Lipidology, 2007, 2, 615-624.	0.5	2
171	Molecular diagnosis of hypobetalipoproteinemia: An ENID review. Atherosclerosis, 2007, 195, e19-e27.	0.4	152
172	A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 677-681.	1.1	125
173	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thrombosis and Haemostasis, 2007, 98, 1362-1367.	1.8	15
174	Effect of the ?420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. Journal of Internal Medicine, 2007, 262, 104-112.	2.7	60
175	Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. Free Radical Biology and Medicine, 2007, 43, 1255-1262.	1.3	110
176	Multiple food hypersensitivity as a cause of refractory chronic constipation in adults. Scandinavian Journal of Gastroenterology, 2006, 41, 498-504.	0.6	26
177	Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis, 2006, 186, 433-440.	0.4	97
178	CETP levels rather than polymorphisms as markers of coronary risk: Healthy athlete with high HDL-C and coronary diseaseâ€"effectiveness of probucol. Atherosclerosis, 2006, 186, 225-227.	0.4	3
179	Unexplained Elevated Serum Pancreatic Enzymes: A Reason to Suspect Celiac Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 455-459.	2.4	32
180	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism: Clinical and Experimental, 2006, 55, 662-668.	1.5	19

#	Article	IF	Citations
181	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. Metabolism: Clinical and Experimental, 2006, 55, 1308-1316.	1.5	15
182	Association of estrogen receptor Î± gene with Alzheimer's disease: A case-control study. Journal of Alzheimer's Disease, 2006, 9, 273-278.	1.2	35
183	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. International Journal of Molecular Medicine, 2006, 18, 449.	1.8	6
184	Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics. Rapid Communications in Mass Spectrometry, 2006, 20, 2433-2440.	0.7	35
185	Association between apolipoprotein E e4 allele and apathy in probable Alzheimer's disease.. Acta Psychiatrica Scandinavica, 2006, 113, 59-63.	2.2	33
186	The c.43_44insCTG variation inPCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Human Mutation, 2006, 27, 460-466.	1.1	74
187	A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. American Journal of Physiology - Renal Physiology, 2006, 290, G1170-G1176.	1.6	14
188	Gene expression in mouse spermatogenesis during ontogenesis. International Journal of Molecular Medicine, 2006, 17, 523-8.	1.8	7
189	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. International Journal of Molecular Medicine, 2006, 17, 539-46.	1.8	4
190	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. International Journal of Molecular Medicine, 2006, 18, 449-55.	1.8	8
191	A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily. British Journal of Dermatology, 2005, 153, 1019-1022.	1.4	21
192	No association between the cystatin C gene polymorphism and Alzheimer's disease: A case-control study in an Italian population. Journal of Alzheimer's Disease, 2005, 7, 291-295.	1.2	10
193	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome. Molecular Diagnosis and Therapy, 2005, 9, 201-204.	1.3	4
194	Anti-Actin Antibodies in Celiac Disease: Correlation with Intestinal Mucosa Damage and Comparison of ELISA with the Immunofluorescence Assay. Clinical Chemistry, 2005, 51, 917-920.	1.5	23
195	Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis, 2005, 180, 311-318.	0.4	60
196	Chronic constipation and food intolerance: A model of proctitis causing constipation. Scandinavian Journal of Gastroenterology, 2005, 40, 33-42.	0.6	46
197	Cystatin C levels are decreased in acute myocardial infarction. International Journal of Cardiology, 2005, 101, 213-217.	0.8	28
198	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 361-367.	1.1	11

#	Article	IF	Citations
199	Gastrointestinal symptoms in infancy: A population-based prospective study. Digestive and Liver Disease, 2005, 37, 432-438.	0.4	152
200	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome. , 2005, 9, 201.		2
201	A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke. JAMA - Journal of the American Medical Association, 2004, 291, 2221.	3.8	227
202	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. European Journal of Endocrinology, 2004, 150, 831-836.	1.9	0
203	Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. International Journal of Biochemistry and Cell Biology, 2004, 36, 1297-1305.	1.2	8
204	Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. Atherosclerosis, 2004, 172, 309-320.	0.4	47
205	Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis, 2004, 174, 57-65.	0.4	77
206	Autoimmune enteropathy and colitis in an adult patient. Digestive Diseases and Sciences, 2003, 48, 1600-1606.	1.1	45
207	Screening for celiac disease in non-Hodgkin's lymphoma patients: a serum anti-transglutaminase-based approach. Digestive Diseases and Sciences, 2003, 48, 1530-1536.	1.1	13
208	The C(-260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction. Clinical and Experimental Medicine, 2003, 3, 161-165.	1.9	22
209	Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. Atherosclerosis, 2003, 166, 395-400.	0.4	23
210	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. Clinica Chimica Acta, 2003, 328, 91-97.	0.5	3
211	No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease. Neuroscience Letters, 2003, 341, 229-232.	1.0	25
212	Two Italian kindreds carrying the Arg136â†'Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele. Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 93-99.	1.1	12
213	Statins and metabolic syndrome. International Congress Series, 2003, 1253, 243-246.	0.2	3
214	Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. Blood Cells, Molecules, and Diseases, 2003, 31, 57-62.	0.6	15
215	Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. Journal of Lipid Research, 2003, 44, 470-478.	2.0	127
216	Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. Clinical Chemistry, 2003, 49, 861-867.	1.5	192

#	Article	IF	Citations
217	Nutritional Characteristics of a Rural Southern Italy Population: The Ventimiglia di Sicilia Project. Journal of the American College of Nutrition, 2002, 21, 523-529.	1.1	30
218	Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neuroscience Letters, 2002, 335, 147-149.	1.0	40
219	Comparison of Anti-Transglutaminase ELISAs and an Anti-Endomysial Antibody Assay in the Diagnosis of Celiac Disease: A Prospective Study. Clinical Chemistry, 2002, 48, 1546-1550.	1.5	120
220	Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up. Thrombosis and Haemostasis, 2002, 87, 206-210.	1.8	23
221	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. American Journal of Cardiology, 2002, 89, 460-462.	0.7	17
222	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. Journal of Lipid Research, 2002, 43, 407-415.	2.0	24
223	Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. Journal of Lipid Research, 2002, 43, 407-15.	2.0	23
224	Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clinical Chemistry, 2002, 48, 1546-50.	1.5	37
225	Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms. International Journal of Biochemistry and Cell Biology, 2001, 33, 1215-1226.	1.2	7
226	Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up. Atherosclerosis, 2001, 157, 225-231.	0.4	34
227	Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney International, 2001, 59, 1574-1579.	2.6	20
228	ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. European Journal of Epidemiology, 2001, 17, 707-713.	2.5	23
229	Estrogen increases hepatic lipase levels in inbred strains of mice: a possible mechanism for estrogen-dependent lowering of high density lipoprotein. Molecular and Cellular Biochemistry, 2001, 220, 87-93.	1.4	20
230	Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. International Journal of Obesity, 2001, 25, 185-190.	1.6	49
231	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. FEBS Journal, 2000, 267, 4272-4280.	0.2	52
232	A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides. Journal of Biological Chemistry, 2000, 275, 32807-32815.	1.6	71
233	Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, E41-52.	1.1	122
234	Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. , 2000, 267, 4272.		1

#	Article	IF	Citations
235	Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. Kidney International, 1999, 55, 2433-2439.	2.6	15
236	Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. Molecular and Cellular Biochemistry, 1999, 202, 37-46.	1.4	17
237	Rapid screening of the LDL receptor point mutation FH-Genoa/Palermo. , 1999, 13, 412-412.		2
238	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. Journal of Lipid Research, 1999, 40, 901-912.	2.0	18
239	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. Journal of Lipid Research, 1999, 40, 955-959.	2.0	36
240	CAROTID ATHEROSCLEROSIS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, 366-371.	0.5	37
241	Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. Journal of Lipid Research, 1999, 40, 901-12.	2.0	12
242	Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. Journal of Lipid Research, 1999, 40, 955-9.	2.0	28
243	Lipoprotein Profile and High-Density Lipoproteins: Subfractions Distribution in Centenarians. Gerontology, 1998, 44, 106-110.	1.4	22
244	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clinical Chemistry, 1998, 44, 1388-1396.	1.5	25
245	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clinical Chemistry, 1998, 44, 1388-96.	1.5	4
246	Estrogen Up-regulates Apolipoprotein E (ApoE) Gene Expression by Increasing ApoE mRNA in the Translating Pool via the Estrogen Receptor Î±-Mediated Pathway. Journal of Biological Chemistry, 1997, 272, 33360-33366.	1.6	158
247	Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation. Metabolism: Clinical and Experimental, 1997, 46, 1095-1100.	1.5	7
248	Liver is not the unique site of synthesis of Î'2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization. International Journal of Clinical and Laboratory Research, 1997, 27, 207-212.	1.0	27
249	A new apolipoprotein B truncation (apo B-43.7) in familial hypobetalipoproteinemia: Genetic and metabolic studies. Metabolism: Clinical and Experimental, 1996, 45, 1296-1304.	1.5	17
250	HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL₂ Particles. Nephron, 1996, 72, 407-412.	0.9	6
251	Plasma Lipid, Apolipoprotein and Lp(a) Levels in Elderly Normolipidemic Women: Relationships with Coronary Heart Disease and Longevity. Gerontology, 1995, 41, 260-266.	1.4	23
252	Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia. Journal of Clinical Apheresis, 1995, 10, 96-100.	0.7	7

#	Article	IF	Citations
253	Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 247-251.	1.1	244
254	Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a). Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2165-2175.	1.1	13
255	Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: Effects of l-thyroxine substitution therapy. Metabolism: Clinical and Experimental, 1995, 44, 1283-1287.	1.5	10
256	Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia. Thrombosis and Haemostasis, 1995, 74, 1015-1019.	1.8	29
257	Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thrombosis and Haemostasis, 1995, 74, 1015-9.	1.8	6
258	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. Clinica Chimica Acta, 1994, 224, 111-118.	0.5	7
259	Effects of gemfibrozil in hyperlipidemic patients with or without diabetes. Current Therapeutic Research, 1993, 53, 381-393.	0.5	2
260	Transient Neonatal Hypercholesterolemia. Hormone and Metabolic Research, 1993, 25, 271-274.	0.7	1
261	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48.. Journal of Lipid Research, 1993, 34, 1957-1967.	2.0	19
262	Postprandial lipemia in subjects with hypobetalipoproteinemia and a single intestinal allele for apoB-48. Journal of Lipid Research, 1993, 34, 1957-67.	2.0	19
263	Increased thromboxane biosynthesis in type IIa hypercholesterolemia.. Circulation, 1992, 85, 1792-1798.	1.6	174
264	Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. Digestive Diseases and Sciences, 1992, 37, 1441-1446.	1.1	64
265	Thrombin-antithrombin III complexes in type II diabetes mellitus. Journal of Diabetes and Its Complications, 1992, 6, 7-11.	1.2	29
266	Follow-Up of Lipid and Apoprotein Levels in Renal Transplant Recipients. Nephron, 1991, 58, 255-256.	0.9	10
267	Apolipoprotein profile in type II diabetic patients with and without coronary heart disease. Acta Diabetologica Latina, 1990, 27, 371-377.	0.2	10
268	Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus. New England Journal of Medicine, 1990, 322, 1769-1774.	13.9	565
269	Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis, 1989, 79, 79-83.	0.4	46
270	Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: A comparison with type IV hyperlipoproteinemic patients. Metabolism: Clinical and Experimental, 1989, 38, 601-602.	1.5	18

#	Article	IF	Citations
271	Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic control. Diabetes Research, 1989, 10, 7-12.	0.1	14
272	Diagnostic use of fructosamine assay in the control of type II diabetes mellitus. Acta Diabetologica Latina, 1988, 25, 63-68.	0.2	3
273	Correlation between different degree and duration of metabolic control and thyroid hormone levels in type 1 and type 2 diabetics. Acta Diabetologica Latina, 1983, 20, 341-346.	0.2	0
274	Platelet activation after adrenergic stimulation in hypertensive patients: effects of acebutolol. European Heart Journal, 1983, 4, 295-299.	1.0	6
275	Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thrombosis Research, 1982, 26, 359-370.	0.8	78
276	Enhanced Platelet Release Reaction in Insulin-Dependent and Insulin-Independent Diabetic Patients. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1982, 12, 275-281.	0.5	13
277	Platelet Sensitivity to Prostacyclin and Thromboxane Production in Hyperlipidemic Patients. Thrombosis and Haemostasis, 1982, 48, 018-020.	1.8	61